Evaluation of HER2/neu Oncoprotein in Serum & Tissue Samples of Women with Breast Cancer

Overview

Journal Indian J Med Res

Specialty General Medicine

Date 2016 Oct 18

PMID 27748278

Citations 6

Authors

Shailaja Shukla

Bhawana Komal Singh

Om Prakash Pathania

Manjula Jain

Affiliations

Soon will be listed here.

Abstract

Background & Objectives: The proto-oncogene HER2/neu has been extensively studied in breast cancer patients. Serum levels of HER2/neu by ELISA in breast cancer patients were compared with tissue HER2/neu expression and with other clinicopathological parameters with the aim to investigate whether the serum assay could replace the established tests (IHC/FISH) for HER-2 status.

Methods: Blood and Tru-cut biopsy samples were collected for determining HER2/neu status in 64 breast cancer patients. The tissue specimens were processed routinely and immunohistochemistry (IHC) for HER2/ER/PR (oestrogen/progesterone receptors) performed. Fluorescence in-situ hybridization (FISH) was performed on all HER2/neu 2 positive cases. Sixty age matched healthy females and females with benign breast disease were taken as controls for ELISA.

Results: Of the 64 breast cancer cases, 25 (39.1%) had elevated serum HER2/neu levels accompanied with increased tissue expression of HER2/neu receptors. On IHC, HER2/neu score was 3+ in 24 (37.5%) cases, 2+ in three (4.6%), 1+ in 18 (28.1%); while 19 cases (29.7%) showed no HER2/neu expression. o0 f the three 2+ cases on IHC, two showed amplification on FISH. Twenty one (32.8%) patients were ER positive and 17 (26.6%) were PR positive. There was a significant correlation (P<0.001) of serum HER2 concentration with tumour size, lymph node involvement, stage of disease and histological grade. Serum HER2/neu levels showed a negative correlation with ER status (P=0.047) but no correlation with PR status.

Interpretation & Conclusions: The results suggest that elevated serum HER2 level was associated with a clinicopathological aggressive phenotype of breast carcinoma and was related to tissue HER2 overexpression. Therefore, serum HER2 may be useful for monitoring the course of the disease and response to treatment.

Citing Articles

A Novel NanoMIP-SPR Sensor for the Point-of-Care Diagnosis of Breast Cancer.

Erol K, Hasabnis G, Altintas Z Micromachines (Basel). 2023; 14(5).

PMID: 37241709 PMC: 10221050. DOI: 10.3390/mi14051086.

The diagnostic significance of circulating miRNAs and metabolite profiling in early prediction of breast cancer in Egyptian women.

El-Toukhy S, El-Daly S, Kamel M, Nabih H J Cancer Res Clin Oncol. 2022; 149(8):5437-5451.

PMID: 36459290 PMC: 10349790. DOI: 10.1007/s00432-022-04492-2.

Circulating proteins as predictive and prognostic biomarkers in breast cancer.

Veyssiere H, Bidet Y, Penault-Llorca F, Radosevic-Robin N, Durando X Clin Proteomics. 2022; 19(1):25.

PMID: 35818030 PMC: 9275040. DOI: 10.1186/s12014-022-09362-0.

Comparison of Her2/Neu Oncoprotein in Serum and Tissue Samples in Women with Breast Cancer.

Pokhrel R, Yadav B, Sharma N, Sharma V, Tuladhar E, Raut M Asian Pac J Cancer Prev. 2022; 23(2):429-433.

PMID: 35225453 PMC: 9272608. DOI: 10.31557/APJCP.2022.23.2.429.

Impact of Molybdenum Compounds as Anticancer Agents.

Odularu A, Ajibade P, Mbese J Bioinorg Chem Appl. 2019; 2019:6416198.

PMID: 31582964 PMC: 6754869. DOI: 10.1155/2019/6416198.

References

Imoto S, Wada N, Hasebe T, Ochiai A, Kitoh T . Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast. Int J Cancer. 2006; 120(2):357-61. DOI: 10.1002/ijc.22166. View

Wang S, Saboorian M, Frenkel E, Hynan L, Gokaslan S, Ashfaq R . Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol. 2000; 53(5):374-81. PMC: 1731196. DOI: 10.1136/jcp.53.5.374. View

Krainer M, Brodowicz T, Zeillinger R, Wiltschke C, SCHOLTEN C, Seifert M . Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology. 1997; 54(6):475-81. DOI: 10.1159/000227606. View

Lee S, Lee J, Yu J, Ko B, Kim H, Son B . Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer. BMC Cancer. 2014; 14:929. PMC: 4295268. DOI: 10.1186/1471-2407-14-929. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Goksel G, Taneli F, Uslu R, Ulman C, Dinc G, Coskun T . Serum her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer. J Int Med Res. 2007; 35(2):165-72. DOI: 10.1177/147323000703500201. View

Kong S, Kang J, Kwon Y, Kang H, Chung K, Kang S . Serum HER-2 concentration in patients with primary breast cancer. J Clin Pathol. 2006; 59(4):373-6. PMC: 1860357. DOI: 10.1136/jcp.2005.029603. View

Sorensen P, Jakobsen E, Langkjer S, Bokmand S, Ostergaard B, Olsen D . Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin Chem Lab Med. 2009; 47(9):1117-23. DOI: 10.1515/CCLM.2009.241. View

Tchou J, Lam L, Li Y, Edwards C, Ky B, Zhang H . Monitoring serum HER2 levels in breast cancer patients. Springerplus. 2015; 4:237. PMC: 4456592. DOI: 10.1186/s40064-015-1015-6. View

10.

Thriveni K, Deshmane V, Bapsy P, Krishnamoorthy L, Ramaswamy G . Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. Indian J Med Res. 2007; 125(2):137-42. View

11.

James R, Thriveni K, Krishnamoorthy L, Deshmane V, Bapsy P, Ramaswamy G . Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer. Indian J Med Res. 2011; 133:70-5. PMC: 3100149. View

12.

Pallud C, Guinebretiere J, Guepratte S, Hacene K, Neumann R, Carney W . Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. Anticancer Res. 2005; 25(2B):1433-40. View

13.

Allred D, Harvey J, Berardo M, Clark G . Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11(2):155-68. View

14.

Asgeirsson K, Agrawal A, Allen C, Hitch A, Ellis I, Chapman C . Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res. 2007; 9(6):R75. PMC: 2246171. DOI: 10.1186/bcr1788. View

15.

Andersen T, Paus E, Nesland J, McKenzie S, Borresen A . Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol. 1995; 34(4):499-504. DOI: 10.3109/02841869509094014. View

16.

Isola J, Holli K, Oksa H, Teramoto Y, Kallioniemi O . Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer. 1994; 73(3):652-8. DOI: 10.1002/1097-0142(19940201)73:3<652::aid-cncr2820730324>3.0.co;2-4. View

17.

Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri M . c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation. Tumori. 2006; 92(4):311-7. DOI: 10.1177/030089160609200409. View

18.

Mori S, Mori Y, Mukaiyama T, Yamada Y, Sonobe Y, Matsushita H . In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn J Cancer Res. 1990; 81(5):489-94. PMC: 5918074. DOI: 10.1111/j.1349-7006.1990.tb02596.x. View

19.

Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I . Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol. 2008; 19(5):883-90. DOI: 10.1093/annonc/mdm585. View

20.

Ryu D, Lee C . Impact of Serum HER2 Levels on Survival and Its Correlation with Clinicopathological Parameters in Women with Breast Cancer. J Breast Cancer. 2012; 15(1):71-8. PMC: 3318178. DOI: 10.4048/jbc.2012.15.1.71. View